Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Open-Label Study of TAK-625 in Japanese Patients with PFIC
jRCT2031220356Phase 3Completed
- Sponsor
- Takeda
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of maralixibat in progressive familial intrahepatic cholestasis (PFIC) (2 cohorts), sponsored by Takeda. Primary endpoint: Change in average morning ItchRO (Obs) severity score from baseline to Weeks 15–26. Started Jan 2023; status: completed.
02
Drugs
maralixibat
03
Conditions
progressive familial intrahepatic cholestasis (PFIC)
Beyond the preview
Go deeper on jRCT2031220356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220356.